Future studies focusing on mouse models of PD, including MitoPark and LRRK2 transgenic mice, should provide additional insights relevant to gut microbial metabolism of l-dopa and its inhibition by Mito-ortho-HNK. This evidence concerns the gene LRRK2 and Parkinson disease.